Lymphoma Research Foundation: FDA Approves Selinexor for Diffuse Large B-cell Lymphoma
June 27, 2020
June 27, 2020
NEW YORK, June 27 -- The Lymphoma Research Foundation issued the following news:
On June 22, 2020, the U.S. Food and Drug Administration (FDA) announced it has approved selinexor (XPOVIO, Karyopharm Therapeutics, Inc.), a single-agent oral tablet, for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.
This is the firs . . .
On June 22, 2020, the U.S. Food and Drug Administration (FDA) announced it has approved selinexor (XPOVIO, Karyopharm Therapeutics, Inc.), a single-agent oral tablet, for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.
This is the firs . . .